OS Therapies announces development of two ADC therapeutic candidate

OS Therapies announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the company’s proprietary SiLinker technology. The company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will target Breast, Lung and Gastric Cancer; and Ovarian, Fallopian Tube and Primary Peritoneal Cancer, respectively. The company is advancing its tADC platform through successive product development de-risking milestones and intends to out-license certain therapeutic candidates and components that are strategic to potential partners’ pipelines – particularly the ph-sensitive SiLinker. The company’s first tADC asset OST-tADC-FRa-H has achieved proof of concept in animal models of ovarian cancer. With the additional two constructs now added to the pipeline, the company is positioning itself to become a provider of intellectual property for new therapeutic product development to partners. All while continuing to focus its internal resources on bringing to market the OST-HER2 off-the-shelf immunotherapy cancer vaccine platform for canines with osteosarcoma, and for humans with osteosarcoma and other HER2 positive cancers such as breast cancer and colorectal cancer.